2010, Dosage and Drug Pricing - Pharmacist Digest

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

2010

Dosage

Drug Pricing

The Fourth Circuit Upholds CMS’ Definition of “Line-Extension Drug” and “New Formulation”

FDA Law Blog: Biosimilars

APRIL 16, 2024

Under the Medicaid Drug Rebate statute, a pharmaceutical manufacturer whose drug prices increase faster than the rate of inflation must pay additional per-unit rebates to the program. NDA or BLA drugs). Vanda Pharmaceuticals, Inc. Centers for Medicare and Medicaid Servs., 23-1457 (4th Cir.

Dosage

Dosage Drug Pricing Pharmaceutical Manufacturing

Exforge antitrust settlement caps Novartis’ year of legal disputes

Pharmaceutical Technology

JANUARY 6, 2023

The alleged actions violated the Hatch-Waxman Act, formally known as the “Drug Price Competition and Patent Term Restoration Act of 1984,” which allows generic manufacturers to market their generic versions of previously approved generic medications. These actions allegedly led to the extension of Novartis’ patents.

Documentation

Documentation Hospitals Dosage Drug Pricing

The Fourth Circuit Upholds CMS’ Definition of “Line-Extension Drug” and “New Formulation”

Exforge antitrust settlement caps Novartis’ year of legal disputes

Stay Connected